#MRNAVaccine

The safety and efficacy of mRNA vaccines have returned to the spotlight following new regulatory actions and heightened public debate, but the scientific community continues to reaffirm their vital role in combating the COVID-19 pandemic. Recent scrutiny, triggered by policy changes from the U.S. Food and Drug Administration (FDA), is prompting fresh discussion amid persistent misinformation and growing public concerns—even as evidence underscores overwhelming benefits for both individuals and public health at large (ABC News).

A growing chorus of scientists is questioning the United States National Institutes of Health’s (NIH) high-profile effort to develop a universal flu vaccine, after it was revealed that the $500 million project relies on older, 20th-century vaccine technology rather than cutting-edge approaches. The controversy, which centers around the scientific and strategic direction of one of the world’s most ambitious attempts to eliminate seasonal influenza, has raised broader concerns about how public health investments are prioritized and the pace of innovation in vaccine development. For Thailand, where seasonal influenza takes a persistent toll each year, the debate underscores the complexities of global vaccine progress and the quest for more effective protection against a virus that continues to mutate and evade immunity.